Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience ; day:3 ; month:7 ; year:2021 ; pages:1-10
European journal of nuclear medicine and molecular imaging ; (3.7.2021), 1-10
- Urheber
-
Heinze, Britta
Schirbel, Andreas
Nannen, Lukas
Michelmann, David
Hartrampf, Philipp E.
Bluemel, Christina
Schneider, Magdalena
Herrmann, Ken
Haenscheid, Heribert
Faßnacht, Martin
Buck, Andreas K.
Hahner, Stefanie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-021-05477-y
- URN
-
urn:nbn:de:101:1-2021101321434056513086
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heinze, Britta
- Schirbel, Andreas
- Nannen, Lukas
- Michelmann, David
- Hartrampf, Philipp E.
- Bluemel, Christina
- Schneider, Magdalena
- Herrmann, Ken
- Haenscheid, Heribert
- Faßnacht, Martin
- Buck, Andreas K.
- Hahner, Stefanie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients
Novel CYP11B-ligand [\(^123/131}\)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
A theranostic approach for adrenocortical neoplasia based on high adrenal CXCR4 expression [Abstract]
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Radiopharmaceuticals for treatment of adrenocortical carcinoma
Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer [Abstract]
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"
Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
Peptide receptor radionuclide therapy for sarcoidosis
Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients
Novel CYP11B-ligand [\(^123/131}\)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
A theranostic approach for adrenocortical neoplasia based on high adrenal CXCR4 expression [Abstract]
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Radiopharmaceuticals for treatment of adrenocortical carcinoma
Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer [Abstract]
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"
Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
Peptide receptor radionuclide therapy for sarcoidosis
Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients
Novel CYP11B-ligand [\(^123/131}\)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
A theranostic approach for adrenocortical neoplasia based on high adrenal CXCR4 expression [Abstract]
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Radiopharmaceuticals for treatment of adrenocortical carcinoma
Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer [Abstract]
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"
Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging